Mirdametinib Mechanism and Clinical Guide: MEK Inhibitor for NF1 Plexiform Neurofibromas

　　1.Overview and FDA Approval

　　Mirdametinib is an oral small-molecule MEK1/MEK2 inhibitor that primarily acts on the RAS/MAPK signaling pathway.The U.S.FDA has approved mirdametinib for the treatment of symptomatic,inoperable plexiform neurofibromas(PN)in patients with neurofibromatosis type 1(NF1)aged 2 years and older.This indication makes it clear that the drug is not a broad-spectrum anticancer agent,but rather a precision targeted therapy option for specific tumor types arising in a particular genetic context.

　　2.Mechanism of Action:Targeting MEK1/2 in the RAS/MAPK Pathway

　　The primary targets of mirdametinib are MEK1 and MEK2 kinases.MEK1/2 are critical upstream regulatory proteins in the extracellular signal-regulated kinase(ERK)pathway,and the RAS-MAPK pathway plays a key role in regulating cell proliferation,growth,and survival.In NF1 patients,abnormalities in the NF1 gene can lead to persistent activation of RAS-related signaling pathways,driving abnormal cell growth.By specifically inhibiting the kinase activity of MEK1/2,mirdametinib blocks this aberrant signaling cascade,thereby reducing downstream ERK phosphorylation and signaling activity,and mechanistically intervening in the abnormal proliferation of tumor cells.

　　3.Clinical Efficacy:Tumor Volume Reduction and Disease Burden

　　The clinical value of mirdametinib is primarily reflected in its ability to control the volume of plexiform neurofibromas.The pivotal ReNeu study evaluated the efficacy of the drug in both adult and pediatric patients with NF1-related PN.Results showed that some patients experienced significant tumor shrinkage after treatment.For patients with complex tumors that cannot be safely and completely surgically removed and who already suffer from pain or other symptoms,this reduction in tumor volume can substantially improve disease burden and enhance quality of life.

　　4.Precision Therapy Positioning and Patient Selection

　　Mirdametinib belongs to the category of precision targeted therapy and is not a traditional cytotoxic chemotherapy drug.Its use is strictly defined:it requires a confirmed diagnosis of NF1,identification of the tumor type as plexiform neurofibroma,and confirmation that the tumor is inoperable and symptomatic.When deciding to use this medication,clinicians must comprehensively evaluate the patient's genetic test results,imaging characteristics,and clinical symptoms to ensure the precision and safety of the treatment decision.